KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Inventory (2016 - 2025)

AbbVie (ABBV) has disclosed Inventory for 14 consecutive years, with $5.0 billion as the latest value for Q4 2025.

  • Quarterly Inventory rose 18.42% to $5.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.0 billion through Dec 2025, up 18.42% year-over-year, with the annual reading at $5.0 billion for FY2025, 18.42% up from the prior year.
  • Inventory for Q4 2025 was $5.0 billion at AbbVie, roughly flat from $4.9 billion in the prior quarter.
  • The five-year high for Inventory was $5.0 billion in Q2 2025, with the low at $3.1 billion in Q3 2021.
  • Average Inventory over 5 years is $3.9 billion, with a median of $4.0 billion recorded in 2023.
  • Peak annual rise in Inventory hit 77.44% in 2021, while the deepest fall reached 16.58% in 2021.
  • Over 5 years, Inventory stood at $3.1 billion in 2021, then rose by 14.42% to $3.6 billion in 2022, then grew by 14.53% to $4.1 billion in 2023, then rose by 2.0% to $4.2 billion in 2024, then rose by 18.42% to $5.0 billion in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $5.0 billion, $4.9 billion, and $5.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.